GoHealth (GOCO): $115M Superpriority Loan and 4.77M Shares Issued

Q: What financing did GoHealth (GOCO) obtain in this Schedule 13D/A?

The filing discloses a $115.0 million Superpriority Senior Secured term loan facility: $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million delayed-draw) and $35.0 million of roll-up term loans.

Q: How many shares were issued to lenders and what dilution does that cause?

The issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock as stated in the filing.

Q: What are the reported beneficial ownership stakes for the Reporting Persons (GOCO)?

Reported stakes include CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%).

[SCHEDULE 13D/A] GoHealth, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

Amendment No. 5 to the Schedule 13D discloses a Superpriority Senior Secured Term Loan package totaling $115.0 million for Norvax, LLC, comprised of $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million as delayed-draw availability) and $35.0 million of roll-up term loans from conversion of existing Class A revolving loans.

The related amendment to the existing credit agreement terminates Class A-1 and Class A revolving commitments, extends the maturity of remaining Class A revolving loans to August 5, 2029, permits pay-in-kind interest with an accrual rate of Adjusted Term SOFR + 8.00% (with at least Adjusted Term SOFR + 4.50% paid in cash), and waives amortization of existing term loans until December 31, 2026. As consideration, the issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock, with customary registration rights. The Board appointed three new directors and three existing directors resigned.

Reporting Persons disclose beneficial ownership stakes in Class A common stock: CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III, L.P. and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%). The filing states the group may be deemed to collectively beneficially own 16,007,486 shares, approximately 58.3% of 15,881,344 reported Class A shares outstanding.

Schedule 13D鞐� 雽€頃� 靾橃爼鞎�(靾橃爼氩堩樃 5)鞚€ Norvax, LLC鞐� 雽€頃� 齑濎暋 $115.0 million 攴滊鞚� 鞀堩嵓頂勲澕鞚挫柎毽嫲靹犾垳鞙� 雼措炒毵岅赴雽€於� 韺偆歆€毳� 瓿奠嫓頃╇媹雼�. 鞚措姅 $40.0 million鞚� 歃夓嫓鞁ろ枆霅橁碃 $40.0 million鞚� 歆€鞐� 鞚胳稖臧€電� 順曧儨鞚� $80.0 million鞚� 鞁犼窚毵岅赴雽€於滉臣旮办〈韥措灅鞀� A 毽臣牍� 雽€於滌潉鞝勴櫂頃� $35.0 million鞚� 搿れ梾(roll-up) 毵岅赴雽€於滊 甑劚霅╇媹雼�.

旮办〈鞁犾毄瓿勳暯鞐� 雽€頃� 甏€霠� 靾橃爼鞎堨潃韥措灅鞀� A-1 氚� 韥措灅鞀� A 毽臣牍� 鞎届爼鞚� 膦呺頃橁碃, 雮晞鞛堧姅韥措灅鞀� A 毽臣牍� 雽€於滌潣毵岅赴毳� 2029雲� 8鞗� 5鞚�搿� 鞐办灔頃橂┌, 雸勳爜鞚挫瀽(pay-in-kind)毳� 項堨毄頃橂悩雸勳爜毳犾潃 Adjusted Term SOFR + 8.00%鞚搓碃斓滌唽頃� Adjusted Term SOFR + 4.50%電� 順勱笀鞙茧 歆€旮夗晿霃勲 攴滌爼頃╇媹雼�. 霕愴暅旮办〈毵岅赴雽€於滌潣鞗愱笀靸來櫂(靸侁皝)鞚� 2026雲� 12鞗� 31鞚�旯岇 鞙犾槇頃╇媹雼�. 雽€臧€搿� 氚滍枆靷姅韸轨爼雽€欤检棎瓴� 4,766,219欤检潣韥措灅鞀� A 欤检嫕鞚� 氚滍枆頄堨溂氅�, 鞚措姅韥措灅鞀� A 氚� B 氤错喌欤检潣頃╆硠氚滍枆欤检嫕欷� 19.99%鞐� 頃措嫻頃橁碃韱奠儊鞝侅澑霌彪甓岇澊攵€鞐悩鞐堨姷雼堧嫟. 鞚挫偓須岆姅鞁犼窚鞚挫偓 3氇呾潉靹犾瀯頄堦碃旮办〈鞚挫偓 3氇呾潃靷瀯頄堨姷雼堧嫟.

氤搓碃鞚鸽摛鞚€ 韥措灅鞀� A 氤错喌欤检棎雽€頃� 鞁れ鞝� 靻岇湢毳� 雼れ潓瓿� 臧欖澊瓿奠嫓頃╇媹雼�: CCP III Cayman GP Ltd. 9,566,028欤� (45.0%), CB Blizzard Holdings C 1,467,653欤� (9.2%), Centerbridge Associates III, L.P. 氚� 甏€霠� 旮瓣磤 2,712,197欤� (17.1%), Blizzard Aggregator, LLC 5,386,178欤� (25.3%), 氚� Jeffrey H. Aronson 9,566,028欤� (45.0%). 鞝滌稖靹滊電� 鞚� 攴鸽９鞚� 頃╈硱靹� 16,007,486欤�, 歃� 氤搓碃霅� 韥措灅鞀� A 氚滍枆欤检嫕 15,881,344欤检潣鞎� 58.3%毳� 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨潓鞚� 氚濏灆雼堧嫟.

Positive

$115.0 million superpriority facility provides immediate liquidity through a mix of new-money term loans and roll-up of existing revolver exposure
Delayed-draw structure allows the borrower to access an additional $40.0 million in staged amounts, with explicit availability caps prior to full funding
Issuance of 4,766,219 subscription shares includes customary registration rights, which may facilitate eventual public liquidity for those shares
Amendment removes certain restrictive covenants and extends maturity of remaining revolver loans to August 5, 2029, creating near-term flexibility

Negative

Lenders received equity equal to 19.99% of combined Class A and B stock, representing material dilution to existing shareholders
The superpriority loan accrues interest at Adjusted Term SOFR + 8.00% with a pay-in-kind component, increasing the effective cost of capital
Priming loan's superpriority status changes creditor recovery priorities and may subordinate existing claimants unless otherwise addressed
Board composition changed with three directors appointed and three resignations, representing a material governance shift

Insights

TL;DR: Credit priming and equity issuance materially alter capital structure and dilute public holders while providing near-term liquidity.

The priming facility and Amendment restructure the borrower鈥檚 secured debt by creating a superpriority tranche and converting existing revolver exposure into term debt, delivering $115.0 million of incremental secured financing. The economics are costly: interest accrues at Adjusted Term SOFR + 8.00% with a substantial pay-in-kind component, and amortization is waived until 2026. Lenders received 4,766,219 subscription shares equal to 19.99% of combined Class A/B stock, which is significant dilution. For minority public holders this increases secured creditor recoveries ahead of existing claims and dilutes equity stakes; however, it also supplies immediate liquidity that may avert more disruptive outcomes.

TL;DR: Transaction is materially impactful; it secures additional funding and governance changes enabling creditor-lender alignment.

The combination of a superpriority priming loan, roll-up of existing revolver debt and issuance of equity to lenders represents a comprehensive recapitalization step. Term and covenant modifications, including removal of certain covenants and extended maturities, create breathing room for operations and potential strategic options. Board composition changes tied to the transactions align governance with consenting creditors. These features make the transaction highly material to stakeholders and likely to influence future restructuring or strategic outcomes.

08/08/2025 - 08:00 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

GoHealth, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

38046W105

(CUSIP Number)

Susanne V. Clark
c/o Centerbridge Partners, L.P., 375 Park Avenue, 11th Floor
New York, NY, 10152
212-672-5000

Benjamin R. Pedersen
Debevoise & Plimpton LLP, 66 Hudson Boulevard
New York, NY, 10001
212-909-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/06/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 搂搂 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Class A Common Stock, par value $0.0001 per share

(b)

Name of Issuer:

GoHealth, Inc.

(c)

Address of Issuer's Principal Executive Offices:

222 W MERCHANDISE MART PLAZA, SUITE 1750, CHICAGO, ILLINOIS , 60654.

Item 1 Comment:

This Amendment No. 5 to Schedule 13D ("Amendment No. 5") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on November 25, 2022 (as amended to date, the "Schedule 13D"), relating to the shares of Class A Common Stock, par value $0.0001 per share (the "Class A Common Stock"), of GoHealth, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Super Priority Term Loan Credit Agreement and Amendment No. 14 to Credit Agreement On August 6, 2025, Norvax, LLC, a Delaware limited liability company (the "Borrower"), entered into a Superpriority Senior Secured Credit Agreement (the "Priming Credit Agreement"), with Blizzard Midco, LLC, a Delaware limited liability company ("Holdings"), the lenders party thereto, and Blue Torch Finance, LLC, as administrative agent and as collateral agent. The Priming Credit Agreement governs a senior secured super priority term loan facility in an aggregate principal amount of $115.0 million consisting of (a) $80.0 million in new-money term loans, of which (i) $40.0 million were funded on August 6, 2025 and (ii) $40.0 million are available as delayed-draw term loans, and (b) $35.0 million of roll-up term loans resulting from the cashless conversion of a corresponding amount of existing Class A revolving loans at par that were outstanding under the Existing Credit Agreement (as defined below) into term loans on a dollar-for-dollar basis. Provided that no default or event of default has occurred and is continuing, delayed-draw term loans will be available to the Borrower on or after October 1, 2025, with the aggregate principal amount of such loans funded prior to November 1, 2025 not to exceed $15.0 million and prior to December 1, 2025, not to exceed $30.0 million, with the full amount available thereafter. On August 6, 2025, the Borrower and Holdings entered into Amendment No. 14 to the Credit Agreement (the "Amendment"), which amends that certain Credit Agreement, dated as of September 13, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, and as further amended by the Amendment, the "Amended Credit Agreement"), by and among the Borrower, Holdings, the lenders party thereto, and Blue Torch Finance, LLC, as administrative agent and as collateral agent. In addition, as a condition to the lenders' entry into the Priming Credit Agreement and the Amendment, the Board of Directors of the Issuer (the "Board") appointed three new directors and three existing directors of the Board resigned and departed the Board. The Amendment amends the Existing Credit Agreement to, among other things, (i) terminate all Class A-1 revolving commitments (with no Class A-1 revolving loans being outstanding on the Closing Date), (ii) terminate all Class A revolving commitments and extend the maturity date of the remaining Class A revolving loans outstanding on the Closing Date to August 5, 2029, (iii) permit the Borrower to pay-in-kind a portion of the interest on the outstanding Existing Term Loans and/or the Class A revolving loans, such loans accruing interest at a rate equal to Adjusted Term SOFR plus 8.00% per annum, of which an amount of interest equal to at least Adjusted Term SOFR plus 4.50% per annum is payable in cash with the remainder of such interest paid-in-kind, and (iv) waive the amortization of the Existing Term Loans until December 31, 2026. The Amendment also incorporates to the Existing Credit Agreement the additional reporting obligations and certain other provisions included in the Priming Credit Agreement and described above, removes each of the total cash leverage covenant, the asset coverage covenant and the budget variance covenant, and provides that an "event of default" under the Priming Credit Agreement shall not constitute an event of default under the Amended Credit Agreement unless the Priming Term Loan Obligations have been accelerated. As consideration for, and as a condition to, the lenders' entry into the Amendment, on August 6, 2025, the Issuer issued to lenders (or their affiliates) holding Class A revolving loans and existing term loans outstanding under the Existing Credit Agreement (the "Subscribers"), pro rata based on their respective holdings thereof, an aggregate of 4,766,219 shares of Class A common stock, par value $0.0001 per share, of the Issuer (the "Subscription Shares"), which represent an aggregate of 19.99% of the total issued and outstanding shares of the Issuer's Class A common stock and Class B common stock, calculated as of immediately prior to the consummation of the transactions contemplated by the Amendment. The Subscribers will be entitled to certain customary registration rights with respect to the Subscription Shares. In connection with the above transactions, certain of the Reporting Persons and NVX Holdings, Inc., a Delaware corporation, executed a Waiver and Consent, dated as of August 6, 2025 (the "Waiver and Consent"), pursuant to which certain of the Reporting Persons and Centerbridge Capital Partners III, L.P., a Delaware limited partnership, waived certain of their rights and provided their consent to the transaction pursuant to that certain (i) Stockholders Agreement, dated as of July 15, 2020 (the "Stockholders Agreement"), by and among the Issuer, Centerbridge Capital Partners III, L.P. and NVX Holdings, and (ii) Registration Rights Agreement, dated as of July 15, 2020 (the "Registration Rights Agreement"), by and among the Issuer and each person identified on the Schedule of Holders attached thereto, including the entities designated as Centerbridge Holders and any of their affiliates and NVX Holdings. The foregoing description of the Waiver and Consent does not purport to be complete and is qualified in its entirety by reference to the full text of the Proposal, which is filed herewith as Exhibit 5 and incorporated herein by reference. In addition, as a condition to the lenders' entry into the Priming Credit Agreement and the Amendment, the Board appointed three new directors and three existing directors of the Board resigned and departed the Board, including Alexander E. Timm and Alan Wheatley who were designated to the Board by Centerbridge Capital Partners III, L.P.

Item 5.

Interest in Securities of the Issuer

(a)

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) - (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 11,115,125 shares of Class A Common Stock outstanding as of May 6, 2025, as provided by the Issuer in the Quarterly Report on Form 10-Q filed by the Issuer on May 16, 2025, plus 4,766,219 shares of Class A Common Stock issued to the Subscribers (as defined and described in further detail in Item 4), plus, as applicable, 5,386,178 shares of Class A Common Stock underlying the LLC Interests held of record by CB Blizzard B: Reporting Person : CCP III Cayman GP Ltd. Amount beneficially owned: 9,566,028 Percent of class : 45.0% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 9,566,028 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 9,566,028 Reporting Person : CB Blizzard Holdings C, L.P. Amount beneficially owned: 1,467,653 Percent of class : 9.2% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 1,467,653 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 1,467,653 Reporting Person : Centerbridge Associates III, L.P. Amount beneficially owned: 2,712,197 Percent of class : 17.1% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 2,712,197 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 2,712,197 Reporting Person : CCP III AIV VII Holdings, L.P. Amount beneficially owned: 2,712,197 Percent of class : 17.1% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 2,712,197 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 2,712,197 Reporting Person : CB Blizzard Co-Invest Holdings, L.P. Amount beneficially owned: 2,712,197 Percent of class : 17.1% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 2,712,197 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 2,712,197 Reporting Person : CB Blizzard Lower Holdings GP A, LLC Amount beneficially owned: 2,712,197 Percent of class : 17.1% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 2,712,197 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 2,712,197 Reporting Person : CB Blizzard Lower Holdings A, L.P. Amount beneficially owned: 2,712,197 Percent of class : 17.1% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 2,712,197 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 2,712,197 Reporting Person : Blizzard Aggregator, LLC Amount beneficially owned: 5,386,178 Percent of class : 25.3% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 5,386,178 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 5,386,178 Reporting Person : CB Blizzard Lower Holdings GP B, LLC Amount beneficially owned: 5,386,178 Percent of class : 25.3% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 5,386,178 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 5,386,178 Reporting Person : CB Blizzard Lower Holdings B, L.P. Amount beneficially owned: 5,386,178 Percent of class : 25.3% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 5,386,178 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 5,386,178 Reporting Person : Jeffrey H. Aronson Amount beneficially owned: 9,566,028 Percent of class : 45.0% Sole power to vote or to direct the vote : 0 Shared power to vote or to direct the vote : 9,566,028 Sole power to dispose or to direct the disposition : 0 Shared power to dispose or to direct the disposition : 9,566,028 CB Blizzard A is the record holder of 2,712,197 shares of Class A Common Stock. CB Blizzard C is the record holder of 1,467,653 shares of Class A Common Stock. CB Blizzard B is the record holder of 5,386,178 LLC Interests. CCP GP is the general partner of CB Blizzard C and may be deemed to share beneficial ownership of the securities held of record by CB Blizzard C. CCP GP is also the general partner of Centerbridge Associates III, L.P., which is the general partner of each of CCP III AIV VII Holdings, L.P. and CB Blizzard Co-Invest Holdings, L.P., which are the owners of CB Blizzard Lower Holdings GP A, LLC, which is the general partner of CB Blizzard A. As a result, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by CB Blizzard A. CCP GP is also the sole manager of Blizzard Aggregator, LLC, which is the owner of CB Blizzard Lower Holdings GP B, LLC, which is the general partner of CB Blizzard B. As a result, each of the foregoing entities may be deemed to share beneficial ownership of the LLC Interests held of record by CB Blizzard. Jeffrey H. Aronson is the sole director of CCP GP and, as a result, may be deemed to share beneficial ownership of the securities held of record by each of CB Blizzard A, CB Blizzard C and CB Blizzard B. However, none of the foregoing should be construed in and of itself as an admission by Mr. Aronson or by any Reporting Person as to beneficial ownership of securities owned by another Reporting Person. In addition, Mr. Aronson expressly disclaims beneficial ownership of the securities held of record by each of CB Blizzard A, CB Blizzard C and CB Blizzard B. By virtue of the agreements made pursuant to the Stockholders Agreement and the matters described in Item 4 above, the Reporting Persons and the Founder Stockholders may constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 (the "Exchange Act"), which group may be deemed to collectively beneficially own 16,007,486 shares of Class A Common Stock of the Issuer, constituting approximately 58.3% of the 15,881,344 shares of the Class A Common Stock outstanding, plus the 5,386,178 shares of Class A Common Stock underlying the LLC Interests held of record by CB Blizzard B and the 6,181,453 shares of Class A Common Stock underlying the LLC Interests held of record by certain of the Founder Stockholders, as calculated on the basis of Rule 13d-3 of the Exchange Act. However, the Reporting Persons expressly disclaim beneficial ownership of the 6,441,458 shares of Class A Common Stock (including the 6,181,453 shares of Class A Common Stock underlying the LLC Interests held of record by certain of the Founder Stockholders) beneficially owned by the Founder Stockholders. The Founder Stockholders have filed a separate Schedule 13D with respect to their interests in the Issuer and the Proposal.

(b)

See Item 5(a) above.

(c)

Except as set forth above, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the other individuals named in Item 2, has effected any transaction in shares of Class A Common Stock since the filing of Amendment No. 5 to Schedule 13D.

(d)

None.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 4 of the Schedule 13D is hereby incorporated by reference into this Item 6.

Item 7.

Material to be Filed as Exhibits.

5. Waiver and Consent dated August 6, 2025

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

CCP III Cayman GP Ltd.

Signature:	/s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Holdings C, L.P.

Signature:	By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

Centerbridge Associates III, L.P.

Signature:	By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CCP III AIV VII Holdings, L.P.

Signature:	By: Centerbridge Associates III, L.P., its general partner, By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Co-Invest Holdings, L.P.

Signature:	By: Centerbridge Associates III, L.P., its general partner, By: CCP III Cayman GP Ltd., its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Lower Holdings GP A, LLC

Signature:	/s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Lower Holdings A, L.P.

Signature:	By: CB Blizzard Lower Holdings GP A, LLC, its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

Blizzard Aggregator, LLC

Signature:	By: CCP III Cayman GP Ltd., its sole manager, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Lower Holdings GP B, LLC

Signature:	/s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

CB Blizzard Lower Holdings B, L.P.

Signature:	By: CB Blizzard Lower Holdings GP B, LLC, its general partner, /s/ Susanne V. Clark
Name/Title:	Susanne V. Clark/Authorized Signatory
Date:	08/08/2025

Jeffrey H. Aronson

Signature:	/s/ Jeffrey H. Aronson
Name/Title:	Jeffrey H. Aronson
Date:	08/08/2025

Source:

FAQ

What financing did GoHealth (GOCO) obtain in this Schedule 13D/A?

The filing discloses a $115.0 million Superpriority Senior Secured term loan facility: $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million delayed-draw) and $35.0 million of roll-up term loans.

How many shares were issued to lenders and what dilution does that cause?

The issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock as stated in the filing.

What are the reported beneficial ownership stakes for the Reporting Persons (GOCO)?

Reported stakes include CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%).

What material changes to the credit agreement were made?

The Amendment terminates Class A-1 and Class A revolving commitments, extends maturity of remaining Class A revolving loans to August 5, 2029, permits pay-in-kind interest with accrual at Adjusted Term SOFR + 8.00%, and waives amortization of existing term loans until December 31, 2026.

Were there governance changes disclosed in the filing?

Yes. The Board appointed three new directors and three existing directors resigned; two of the departing directors were previously designated by Centerbridge.

AG真人官方

[SCHEDULE 13D/A] GoHealth, Inc. SEC Filing

Insights

FAQ

What financing did GoHealth (GOCO) obtain in this Schedule 13D/A?

How many shares were issued to lenders and what dilution does that cause?

What are the reported beneficial ownership stakes for the Reporting Persons (GOCO)?

What material changes to the credit agreement were made?

Were there governance changes disclosed in the filing?

NASDAQ:GOCO

GOCO Rankings

GOCO Latest News

GOCO Latest SEC Filings

GOCO Stock Data

AG真人官方

Trending News

[SCHEDULE 13D/A] GoHealth, Inc. SEC Filing

Insights

Financial Analyst negative

M&A / Capital Structure Specialist positive

FAQ

What financing did GoHealth (GOCO) obtain in this Schedule 13D/A?

How many shares were issued to lenders and what dilution does that cause?

What are the reported beneficial ownership stakes for the Reporting Persons (GOCO)?

What material changes to the credit agreement were made?

Were there governance changes disclosed in the filing?

NASDAQ:GOCO

GOCO Rankings

GOCO Latest News

GOCO Latest SEC Filings

GOCO Stock Data